Desmopressin (DDAVP) and TEG6s in Heart Surgery Coagulation
Official title: Desmopressin Effect on Platelet Function Assessment by Thromboelastography (TEG 6) in Cardiac Surgery
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT07179991 · Data updated 2026-11-12
This study tests whether giving desmopressin after reversal of heparin helps improve clotting in adults undergoing cardiopulmonary bypass during elective heart surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | December 1, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT07179991 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older undergoing elective cardiac surgery with cardiopulmonary bypass who can provide informed consent.
✕Probably not a fit
Patients with contraindications to desmopressin or significant renal impairment may not benefit and could be at risk for adverse effects.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In patients undergoing elective cardiac surgery with CPB, the study examines the use of desmopressin after protamine reversal to improve coagulation as measured by TEG6s platelet mapping. The approach relates to how DDAVP increases von Willebrand factor and factor VIII to support platelet function and clot formation. Viscoelastic testing with TEG6s guides blood product use during the perioperative period. This observational design evaluates real-world use and outcomes rather than randomizing participants. The aim is to see if DDAVP can reduce postoperative bleeding and transfusion needs in this surgical setting.
Why it matters
Potential benefit: If successful, DDAVP could help reduce postoperative bleeding and the need for blood transfusions after cardiac surgery.
How similar studies have gone: Previous work suggests DDAVP can improve hemostasis in patients with qualitative platelet dysfunction and may reduce transfusions in cardiac surgery, but evidence is mixed; this study adds real-world data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 years and above 2. Undergoing elective cardiac surgery with cardiopulmonary bypass 3. Able to provide informed consent Exclusion Criteria: 1. Hyponatremia 2. Allergy to desmopressin or its components 3. History of coronary artery disease with thrombosis 4. Recent history of thromboembolic events (Stroke/TIA/DVTs) 5. Severe Renal Impairment Creatinine Clearance\<30 ml/min 6. Inability to communicate in the English language
Where it's running
-
London Health Sciences Centre
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Satoru Fujii — London Health Sciences Centre
- Study coordinator: Satoru Fujii
- Email: Satoru.Fujii@lhsc.on.ca
- Phone: 5196858500
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.